Brand profile · Biotechnology Research

Immuron

Immuron runs a Biotechnology Research operation from Melbourne, Victoria. Ownership is publicly held; it publishes at immuron.com. The record carries two addresses across two office countries. The record counts 17 people. One Australian registration (ABN) is a confirmed match. The latest round on record is Grant at US$2.3M. The record links nine similar brands, most of them in Biotechnology Research.

Profile live Public Company 1 entity ABN 2 office countries US$ 2.3M Grant
Registry verified · ABR

Key facts

Counted staff
17
self-reported 11–50 band
Founded
Not recorded
Legal entities
1
ABR
Office countries
2
2 addresses
Funding rounds
4
Grant · Sep 2024 · US$ 2.3M
Company type
Public Company
self-reported
Use this profile Compare Your shortlist

Legal entity

1 brand → 1 confirmed entity
  • IMMURON LIMITED

    ABN80063114045

    VICHigh confidenceMatched on exact nameABR

Legal entities

Immuron: 1 registry entityImmuron is linked to 1 registry entity: IMMURON LIMITED (ABN 80063114045, candidate).ImmuronIMMURON LIMITEDABN 80063114045Candidate · High confidence
Show as table · Immuron: 1 registry entity
Immuron: 1 registry entity
IMMURON LIMITEDABN 80063114045
Confirmed matches0 of 1

A candidate is a name match on the registry, not a confirmed identity, and two candidates are ambiguity rather than a corporate structure.

Description

Immuron Ltd (ASX:IMC) (NASDAQ:IMRN) is an Australian based and globally integrated biopharmaceutical company that has developed two commercially available oral immunotherapeutic products for the treatment of gut mediated diseases.

ACCEPTABLE USE POLICY We welcome your comments on our page but we ask that you help us comply with the Therapeutic Goods Advertising Code. Please consider these guidelines before commenting. We will remove any comments that may result in us breaching the Code. We love when you comment and tag your friends and family on our posts but we ask that you do not:

  • endorse our product if you are:

o an employee or contractor of a government authority, a hospital or a healthcare facility o a health practitioner, health professional or medical researcher o involved with the production, sale, supply or marketing of our product o not using your own name on this social media platform

  • imply that a government authority, a hospital or a healthcare facility endorse our product
  • make comments about how a product works for you outside of its intended purpose, as these comments can be dangerous or misleading - our products are developed for particular purposes, as stated on the label and/or in our advertising
  • make comments about serious conditions, diseases, ailments or defects, such as comments about how a product helped with your treatment of a serious disease or how it will relieve a tagged person's serious condition

We also have an obligation to make sure any advertisements we make, including endorsements and testimonials, are not misleading. Therefore we promise to disclose:

  • where a person has been, or will be, compensated for making a testimonial
  • where we have actors making the testimonial, such as in cases where the original person who made the testimonial does not want to appear in our advertisement
  • where the person making the testimonial is an immediate family member of anyone employed by our company.

Locations

2
Countries with an office address2 addresses on record
AustraliaprimaryUnited States

Country footprint

Offices in 2 countriesCountry footprint: 2 countries, primary AU. Codes: AU, US.2 countriesprimary AUAUUS
Show as table · Offices in 2 countries
Offices in 2 countries
Countries2
Primary countryAU

All codes: AU US

Addresses

  • AUSuite 10- 25 Chapman Street; Blackburn North; Melbourne, Victoria 3130Primary
  • US13 Summit Square Center – # 123; Langhorne, PA 19047

Grid intelligence Members

Funding

Last round · 16 September 2024US$ 2.3MGrant
Rounds4
Round typeGrant · non-equity funding
Amount (USD)2,300,000
Stage rank1
Investors named0
Since last round1 yr 4 mo

Funding

4 funding roundsFunding timeline. Latest round 16 Sep 2024: Grant, US$ 2.3M.20242027GrantUS$ 2.3M4 rounds
Show as table · 4 funding rounds
4 funding rounds
Rounds4
Axis2024 to 2027
Grant · 16 Sep 2024US$ 2.3M

Dated rounds only. The axis ends at the date this profile was last observed, not at today.

Spending power

TheGrid Corporate Spending Power index would rate purchasing capacity from registry, scale and activity signals.

Spending power

Signals & hiring

Hiring, headcount and registry-change signals, streamed to members.

Latest signal
Hiring activity
Headcount trend

Financials

Registry-filed capital and financial indicators, standardised by TheGrid.

Paid-up capital
Fiscal period
Registered charges
Revenue
Profit / loss

People & contacts

4 employee profiles on record · names withheld.

Names and titles are intentionally absent from this page. The source relation carries no consent record across the privacy regimes this directory spans, so it is never requested and never stored. Search engines see exactly what you see here.

Counts only. No names are stored here, and none are served.

Notify me about contacts Tell us who you need to reach and we will tell you when a consented source is live.

FAQ

Which legal entity operates under Immuron?

One Victoria entity on the ABR. IMMURON LIMITED (ABN 80 063 114 045), high confidence.

How many people work at Immuron?

The record holds 17 counted staff profiles at January 2026, inside the self-reported 11–50 band.

Where does Immuron have offices?

Two addresses on record across 2 countries. Primary: Suite 10- 25 Chapman Street, Blackburn North, Melbourne, Victoria 3130.

Has Immuron raised funding?

Four rounds. Latest 16 September 2024: grant, US$2,300,000.

Which companies are listed alongside Immuron?

7 profiles list Immuron as a peer — 73rd percentile in Biotechnology Research. It lists ten peers of its own. Coffee Microcaps and Anatara Lifesciences Ltd list it back.

What is Immuron's website?